SENSCIS试验亚组:系统性硬化相关间质性肺病患者的甲襞毛细血管镜表现
该研究为SENSCIS试验的甲襞毛细血管镜亚组,在基线和第52周评估尼达尼布或安慰剂治疗患者的微血管改变。整体两组各项NC指标无显著变化;在快速FVC下降风险因素患者中,安慰剂组平均毛细血管密度数值下降而尼达尼布组保持稳定。在ILD进展患者中,尼达尼布组平均毛细血管密度数值增加而安慰剂组保持稳定。
要点
- 整体尼达尼布组与安慰剂组第52周各项甲襞毛细血管镜指标较基线无显著变化。
- 有快速FVC下降风险因素者(n=38),安慰剂组平均毛细血管密度数值下降,尼达尼布组保持稳定。
- ILD进展者(n=11),尼达尼布组平均毛细血管密度数值增加,安慰剂组保持稳定。
核心结论
- 在SENSCIS试验亚组中,52周甲襞毛细血管镜评估的毛细血管密度变化的数值差异可能提示尼达尼布对有ILD进展风险患者的潜在效应。
研究设计与样本
- SENSCIS试验的甲襞毛细血管镜亚组,患者在基线和第52周接受甲襞毛细血管镜检查。
- 比较尼达尼布组与安慰剂组的毛细血管密度(每毫米毛细血管数)、巨大毛细血管、异常形态及有微出血的手指百分比。
主要发现
- 整体安慰剂组或尼达尼布组在基线与第52周之间,任何甲襞毛细血管镜测量均未观察到显著变化。
- 有快速FVC下降风险因素的患者(n=38)中,安慰剂组52周平均毛细血管密度数值下降,尼达尼布组保持稳定。
- 发生ILD进展的患者(n=11)中,尼达尼布组52周平均毛细血管密度数值增加,安慰剂组保持稳定。
- 无快速FVC下降风险因素或第52周无ILD进展的患者中,毛细血管密度无显著变化。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess microvascular changes in nailfold capillaries in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who received nintedanib or placebo in a sub-study of the SENSCIS trial. METHODS: Nailfold capillaroscopy (NC) was performed at baseline and week 52. In the nintedanib and placebo groups, we measured capillary density (number of capillaries/mm), giant capillaries, abnormal shapes and percentage of fingers with microhaemorrhages. In addition, capillary density was evaluated in patients who did/did not have risk factors for rapid forced vital capacity (FVC) decline at baseline and who did/did not have ILD progression (absolute decline in FVC % predicted >5% or death) from baseline to week 52. RESULTS: Between baseline and week 52, no notable changes were observed in any NC measurement in the overall placebo or nintedanib groups. In patients with risk factors for rapid FVC decline (n=38), there was a numerical reduction in mean capillary density over 52 weeks with placebo, but it remained stable with nintedanib. Among patients who had ILD progression (n=11), there was a numerical increase in mean capillary density over 52 weeks with nintedanib, but it remained stable with placebo. There were no notable changes in capillary density among patients who did not have risk factors for rapid FVC decline at baseline or ILD progression at week 52. CONCLUSION: In a substudy of the SENSCIS trial, numerical differences in changes in capillary density assessed by NC over 52 weeks may suggest a potential effect of nintedanib in patients at risk of ILD progression.
引用
- Smith V, Denton CP, Herrick AL, et al. Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: a substudy of the SENSCIS trial. RMD Open. 2025. PMID: 41107055. doi:10.1136/rmdopen-2025-005704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。